The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank

James Dale, Caron Paterson, Ann Tierney, Stuart H Ralston, David M Reid, Neil Basu, John Harvie, Neil D McKay, Sarah Saunders, Hilary Wilson, Robin Munro, Ruth Richmond, Derek Baxter, Michael McMahon, John McLaren, Vinod Kumar, Stefan Siebert, Iain McInnes, Duncan Porter

Research output: Contribution to journalArticle

5 Citations (Scopus)
5 Downloads (Pure)

Abstract

BACKGROUND: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers METHODS: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months RESULTS: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples CONCLUSIONS: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.

Original languageEnglish
Article number461
JournalBMC Musculoskeletal Disorders
Volume17
DOIs
Publication statusPublished - 9 Nov 2016

Fingerprint

Rheumatoid Arthritis
Cohort Studies
Aptitude
Scotland
Phenotype
Quality of Life
Antirheumatic Agents
Translational Medical Research
Information Services
Methotrexate
Health Services
Arthritis
Psychiatry
Foot
Anxiety
Hand
Biomarkers
Demography
Urine
Depression

Cite this

Dale, J., Paterson, C., Tierney, A., Ralston, S. H., Reid, D. M., Basu, N., ... Porter, D. (2016). The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 17, [461]. https://doi.org/10.1186/s12891-016-1318-y

The Scottish Early Rheumatoid Arthritis (SERA) Study : an inception cohort and biobank. / Dale, James; Paterson, Caron; Tierney, Ann; Ralston, Stuart H; Reid, David M; Basu, Neil; Harvie, John; McKay, Neil D; Saunders, Sarah; Wilson, Hilary; Munro, Robin; Richmond, Ruth; Baxter, Derek; McMahon, Michael; McLaren, John; Kumar, Vinod; Siebert, Stefan; McInnes, Iain; Porter, Duncan.

In: BMC Musculoskeletal Disorders, Vol. 17, 461, 09.11.2016.

Research output: Contribution to journalArticle

Dale, J, Paterson, C, Tierney, A, Ralston, SH, Reid, DM, Basu, N, Harvie, J, McKay, ND, Saunders, S, Wilson, H, Munro, R, Richmond, R, Baxter, D, McMahon, M, McLaren, J, Kumar, V, Siebert, S, McInnes, I & Porter, D 2016, 'The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank', BMC Musculoskeletal Disorders, vol. 17, 461. https://doi.org/10.1186/s12891-016-1318-y
Dale, James ; Paterson, Caron ; Tierney, Ann ; Ralston, Stuart H ; Reid, David M ; Basu, Neil ; Harvie, John ; McKay, Neil D ; Saunders, Sarah ; Wilson, Hilary ; Munro, Robin ; Richmond, Ruth ; Baxter, Derek ; McMahon, Michael ; McLaren, John ; Kumar, Vinod ; Siebert, Stefan ; McInnes, Iain ; Porter, Duncan. / The Scottish Early Rheumatoid Arthritis (SERA) Study : an inception cohort and biobank. In: BMC Musculoskeletal Disorders. 2016 ; Vol. 17.
@article{897126e420a240a3ac56089234159c02,
title = "The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank",
abstract = "BACKGROUND: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers METHODS: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months RESULTS: Results are available for 1073 patients; at baseline, 76 {\%} were classified as RA and 24 {\%} as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 {\%} patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 {\%}, p = 0.0005). 24 {\%} patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 {\%}) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples CONCLUSIONS: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.",
author = "James Dale and Caron Paterson and Ann Tierney and Ralston, {Stuart H} and Reid, {David M} and Neil Basu and John Harvie and McKay, {Neil D} and Sarah Saunders and Hilary Wilson and Robin Munro and Ruth Richmond and Derek Baxter and Michael McMahon and John McLaren and Vinod Kumar and Stefan Siebert and Iain McInnes and Duncan Porter",
note = "Acknowledgements The study was conceived by the Scottish Collaborative Arthritis Research network, and data were collected by clinical research teams across Scotland. We would like to thank all the patients, clinical and nursing colleagues who have contributed their time and support to the study Funding The SERA study was jointly supported by the Chief Scientist’s Office Scotland (ETM-40) and Pfizer Ltd",
year = "2016",
month = "11",
day = "9",
doi = "10.1186/s12891-016-1318-y",
language = "English",
volume = "17",
journal = "BMC Musculoskeletal Disorders",
issn = "1471-2474",
publisher = "BMC",

}

TY - JOUR

T1 - The Scottish Early Rheumatoid Arthritis (SERA) Study

T2 - an inception cohort and biobank

AU - Dale, James

AU - Paterson, Caron

AU - Tierney, Ann

AU - Ralston, Stuart H

AU - Reid, David M

AU - Basu, Neil

AU - Harvie, John

AU - McKay, Neil D

AU - Saunders, Sarah

AU - Wilson, Hilary

AU - Munro, Robin

AU - Richmond, Ruth

AU - Baxter, Derek

AU - McMahon, Michael

AU - McLaren, John

AU - Kumar, Vinod

AU - Siebert, Stefan

AU - McInnes, Iain

AU - Porter, Duncan

N1 - Acknowledgements The study was conceived by the Scottish Collaborative Arthritis Research network, and data were collected by clinical research teams across Scotland. We would like to thank all the patients, clinical and nursing colleagues who have contributed their time and support to the study Funding The SERA study was jointly supported by the Chief Scientist’s Office Scotland (ETM-40) and Pfizer Ltd

PY - 2016/11/9

Y1 - 2016/11/9

N2 - BACKGROUND: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers METHODS: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months RESULTS: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples CONCLUSIONS: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.

AB - BACKGROUND: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers METHODS: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months RESULTS: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples CONCLUSIONS: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.

U2 - 10.1186/s12891-016-1318-y

DO - 10.1186/s12891-016-1318-y

M3 - Article

C2 - 27829394

VL - 17

JO - BMC Musculoskeletal Disorders

JF - BMC Musculoskeletal Disorders

SN - 1471-2474

M1 - 461

ER -